NCT00936650View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

March 31, 2001

Study Completion Date

June 30, 2001

Conditions
Hyperparathyroidism, Primary
Interventions
DRUG

placebo

Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.

DRUG

cinacalcet

Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY